Biodesix Inc. (BDSX) News
Filter BDSX News Items
BDSX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BDSX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest BDSX News From Around the Web
Below are the latest news stories about BIODESIX INC that investors may wish to consider to help them evaluate BDSX as an investment opportunity.
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)Grew full-year revenue to an estimated $71.3 million, an increase of 45%LOUISVILLE, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its preliminary financial results for the fourth quarter and year ended December 31, 2024 (fiscal 2024). The financial results included in this release pertaining to the fourth quarter and fiscal 2024 are preliminary, unaudited, and subject to final review and adjustment. Preliminary Una |
BDSX Stock Rises After Publication of Study Data for Nodify CDT TestBiodesix announces positive study data for its Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal. |
Biodesix Announces Publication of a New Nodify CDT® Clinical Validation StudyAnalysis of 447 patients receiving the Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal reaffirms test performanceLOUISVILLE, Colo., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced a new post-market clinical validation study was published in CHEST Pulmonary Journal that reaffirms the previously established performance of the Nodify CDT® blood-based lung nodule test. Clinica |
Insider Buys Additional US$234k In Biodesix StockPotential Biodesix, Inc. ( NASDAQ:BDSX ) shareholders may wish to note that the Independent Director, Jack Schuler... |
Biodesix (BDSX) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerThe heavy selling pressure might have exhausted for Biodesix (BDSX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
Biodesix Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagBiodesix ( NASDAQ:BDSX ) Third Quarter 2024 Results Key Financial Results Revenue: US$18.2m (up 35% from 3Q 2023). Net... |
Biodesix Inc (BDSX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...Biodesix Inc (BDSX) reports a 35% revenue increase, driven by lung diagnostic testing, despite facing weather-related disruptions and rising expenses. |
Biodesix, Inc. (BDSX) Reports Q3 Loss, Misses Revenue EstimatesBiodesix (BDSX) delivered earnings and revenue surprises of 12.50% and 1.62%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Biodesix Announces Third Quarter 2024 Results and HighlightsQ3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast Today at 8:30 a.m. ET LOUISVILLE, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2024. “The Biodesix team is pleased to report another solid |
With 47% ownership, Biodesix, Inc. (NASDAQ:BDSX) insiders have a lot riding on the company's futureKey Insights Insiders appear to have a vested interest in Biodesix's growth, as seen by their sizeable ownership The... |